Insider Selling: Personalis (NASDAQ:PSNL) CEO Sells $266,211.88 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 29,612 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares in the company, valued at $1,334,889.14. The trade was a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $6.93 on Friday. Personalis, Inc. has a 52 week low of $2.83 and a 52 week high of $10.95. The firm has a market cap of $615.38 million, a PE ratio of -7.88 and a beta of 1.92. The firm’s fifty day moving average is $7.33 and its 200-day moving average is $6.05.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on PSNL shares. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. HC Wainwright upped their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday. BTIG Research increased their price objective on shares of Personalis from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Lake Street Capital reissued a “buy” rating and set a $11.00 target price on shares of Personalis in a research note on Wednesday. Finally, Needham & Company LLC upped their price target on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Personalis currently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

Institutional Trading of Personalis

Hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC boosted its stake in Personalis by 6.1% during the first quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company’s stock worth $25,231,000 after acquiring an additional 412,762 shares in the last quarter. AIGH Capital Management LLC raised its holdings in shares of Personalis by 4.5% during the first quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company’s stock valued at $13,931,000 after purchasing an additional 169,884 shares during the period. Aberdeen Group plc raised its holdings in shares of Personalis by 35.7% during the third quarter. Aberdeen Group plc now owns 2,387,947 shares of the company’s stock valued at $15,569,000 after purchasing an additional 628,450 shares during the period. Blue Water Life Science Advisors LP boosted its position in shares of Personalis by 42.6% during the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after purchasing an additional 500,900 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after buying an additional 851,422 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.